Table 1.
Antibody response and new COVID-19 events, total 368/503 patients with results at one year.
| Baseline value (AU*/mL) | < 15 | 15–50 | >50 |
|---|---|---|---|
| N (%) | 29 (7.9) | 65 (17.7) | 274 (74.4) |
| one died of mesothelioma | |||
| Female sex, n (%) | 9 (31) | 41 (63.1) | 126 (46) |
| Median age (range) | 48.5 (18-92) | 46.5 (15–83) | 59 (4–87) |
| Immune depression/ immune suppression, n (%) | 1 (3.4) | 9 (14.3) | 43 (15.9) |
| WHO severity scale represented (m: mild; M: moderate; S: severe; C: critical, n, %) | 20 m (68.9); 7 M (24.2); 1 S (3.4); 1 C (3.4) | 49 m (77.8); 11 M (14.3); 2 S (3.2); 3 C (4.8) | 93 m (34.1); 73 M (26.3); 46 S (16.7); 62 C (23) |
| Lost response (<15 AU/mL) | 4 (6.1% of evaluable natural course) | 0 | |
| §RR vs >50 for losing reponse [95% †CI] | 37.5 [2.0–688.0]p = 0.0146 | ||
| Lost response (<3.8 AU/mL) | 0 | 0 | |
| Maintained natural response | 49 | 241 | |
| Lost AU/mL, median [‡IQR], variance; | -4.4 [13; +1-2.5], 1125.2 | -25 [-56; +7], 12184.2 | |
| P for lost AU/mL vs >50 | p = 0.0295 | ||
| Vaccinated, n (% achieved >400 AU/mL) | 4 (75), all baseline >10 AU/mL, 1 with recall dose | 15 (100), 3 with recall dose | 57 (100), 5 with recall dose |
| Acquired response later | 3 | ||
| Repeated clinical COVID-19, n (%=) | 4 (13.8) one admitted for pneumonia | 1 (1.5) | 1 (0.4) |
| RR vs >50 for repeating clinical COVID [95%CI] | 37.7 [4.4–326.9]p = 0.001 | 4.2 [0.3–66.5]p = 0.3067 |
*AU = Arbitrary Units
†CI = Confidence Interval
‡IQR = InterQuartile Range
§RR = Relative Risk